Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Pharmaceutical giant Bristol-Myers Squibb is simply not satisfied with resting on its laurels after its successful partnership earlier this year with Gilead Sciences--a partnership that resulted in the first one-pill-a-day anti-HIV therapy, Atripla. Looking forward, the drugmaker is teaming up with yet another company with the goal of producing a new drug that could further advance the fight against drug-resistant viruses. In September, BMS announced a licensing agreement with Swedish biotechnology firm Medivir. BMS will add its financial muscle and global reach to help develop a potential new medication that Medivir has so far created in-house. Called MIV-170, the drug is a nonnucleoside reverse transcriptase inhibitor. Currently, the National Institutes of Health recommends nonnuke combinations as the best choice for patients going on anti-HIV therapy for the first time. Triple-med cocktails based on Sustiva (which is one of the drugs included in Atripla) or Viramune are the gold standard. Nonnukes have been shown effective at fighting HIV and also to carry less potential for troublesome side effects like diabetes, high cholesterol, or lipodystrophy. However, nonnukes do put patients at high risk of developing drug resistance. And once the virus becomes resistant to one nonnuke, it's possible that the whole class of drugs will no longer be effective. But drug companies are trying to move the fight against HIV to the next level by creating easy-to-tolerate drugs that don't put HIVers at so much risk for drug resistance. According to BMS spokesman Eric Miller, 'MIV-170 has demonstrated excellent potency' in laboratory testing, allowing the company to predict that the human body will likely process the drug effectively. He says research has also found that the drug may fight resistance better than the nonnukes available today. Miller adds that the drug belongs to a new subclass of nonnukes that attacks HIV in slightly different ways than the ones currently available because of its different chemical structure. According to Anthony Urbina, an HIV specialist at St. Vincent's Comprehensive HIV Center in Manhattan, a patient who is already resistant to nonnukes, though, might still be sensitive to a nonnuke with a different chemical structure. But Urbina adds that nonnukes that both operate in new ways and that are also better at fighting resistance would 'greatly add to clinicians' ability to construct effective cocktails' in their patients who have already run through many treatment options. Martin Delaney, founding director of Project Inform, is cautiously optimistic about the future of the nonnuke market. As for the potential success of MIV-170, he points out that BMS and Medivir are competing against the various other companies that are currently developing this class of drugs. 'I think it's a question of who's going to come to the market first,' Delaney says, 'and what kind of resistance profiles their drugs have.' Delaney also has a slightly different take than Miller on BMS and Medivir's research data showing that MIV-170 might have a better ability to fight drug resistance than today's nonnukes. 'We just don't have that much information about the resistance profiles of these drugs,' he says, 'except that it's different from what we have.'
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
'Drag Race' star Q shares she's living with HIV
March 18 2024 3:08 PM
Todrick Hall has long supported the communities he comes from
April 17 2024 12:02 PM
Plus: Featured Video
Latest Stories
La ciencia detrás de U=U ha estado liberando a las personas con VIH durante años
August 23 2024 2:48 PM
Tratamiento y prevención del VIH por inyección: Todo lo que necesita saber
August 23 2024 2:41 PM
Sr. Gay World quiere asegurarse de que estés bien
August 23 2024 2:30 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
With a new case in Sweden, what is the new mpox outbreak and should you be concerned?
August 15 2024 4:48 PM
The freedom of disclosure: David Anzuelo's journey through HIV, art, and advocacy
August 02 2024 12:21 PM
From ‘The Real World’ to real life: How Danny Roberts thrives with HIV
July 31 2024 5:23 PM
The July/Aug 'Treatment Guide' issue of Plus is here!
June 26 2024 3:49 PM
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM